Biogen (XSWX:BIIB) Cyclically Adjusted Book per Share: CHF79.98 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BIIB Biogen Inc XSWX:BIIB
73 GF Score
Price CHF173.46
GF Value CHF153.91
! 10 Warning Signs
View Full Analysis

What is Biogen Cyclically Adjusted Book per Share?

Biogen XSWX:BIIB 73 Cyclically Adjusted Book per Share is CHF79.98 as of Jun. 2026. GuruFocus rates XSWX:BIIB with a GF Score™ of 73/100 and a GF Value™ of CHF153.91. The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Biogen's adjusted book value per share for the three months ended in Jun. 2026 was CHF101.999. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is CHF79.98 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Biogen's average Cyclically Adjusted Book Growth Rate was 10.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 10.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 12.00% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 12.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Biogen was 60.90% per year. The lowest was 8.90% per year. And the median was 13.60% per year.

As of today (2026-09-08), Biogen's current stock price is CHF173.46. Biogen's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was CHF79.98. Biogen's Cyclically Adjusted PB Ratio of today is 2.17.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biogen was 9.94. The lowest was 1.31. And the median was 4.74.


Biogen  (XSWX:BIIB) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biogen's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=173.46/79.98
=2.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biogen was 9.94. The lowest was 1.31. And the median was 4.74.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Biogen Cyclically Adjusted Book per Share Related Terms


Biogen Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Biogen's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Cyclically Adjusted Book per Share Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Biogen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 75.96 79.98

XSWX:BIIB vs OGN, AMRN, NSRX: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted PB Ratio falls into.


XSWX:BIIB
73GF Score
Biogen Inc XSWX:BIIB
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=101.999/333.9520*333.9520
=101.999

Current CPI (Jun. 2026) = 333.9520.

Biogen Quarterly Data

Book Value per Share CPI Adj_Book
201609 54.201 241.428 74.973
201612 57.295 241.432 79.251
201703 53.721 243.801 73.586
201706 53.046 244.955 72.319
201709 58.532 246.819 79.195
201712 58.860 246.524 79.734
201803 63.139 249.554 84.492
201806 60.257 251.989 79.856
201809 66.160 252.439 87.523
201812 65.588 251.233 87.183
201903 70.885 254.202 93.124
201906 69.250 256.143 90.286
201909 76.220 256.759 99.135
201912 75.264 256.974 97.810
202003 71.944 258.115 93.082
202006 67.959 257.797 88.035
202009 63.957 260.280 82.060
202012 62.376 260.474 79.972
202103 65.952 264.877 83.151
202106 65.463 271.696 80.463
202109 65.519 274.310 79.765
202112 68.268 278.802 81.772
202203 70.838 287.504 82.282
202206 79.330 296.311 89.407
202209 86.350 296.808 97.156
202212 86.677 296.797 97.528
202303 88.182 301.836 97.565
202306 89.959 305.109 98.463
202309 89.922 307.789 97.566
202312 88.327 306.746 96.161
202403 93.358 312.332 99.820
202406 98.146 314.175 104.324
202409 95.122 315.301 100.749
202412 102.279 315.605 108.225
202503 102.405 319.799 106.937
202506 97.817 322.561 101.271
202509 98.807 324.800 101.591
202512 99.107 324.054 102.134
202603 99.488 330.213 100.615
202606 101.999 333.952 101.999

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of CHF79.98 mean?
Biogen (XSWX:BIIB) has a Cyclically Adjusted Book per Share of CHF79.98 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Biogen and its competitors.
Is Biogen's Cyclically Adjusted Book per Share too high?
Biogen's current Cyclically Adjusted Book per Share is CHF79.98. Overall, Biogen has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Biogen's Cyclically Adjusted Book per Share compare to OGN and AMRN?
Biogen's Cyclically Adjusted Book per Share of CHF79.98 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Biogen and its competitors. Biogen's current Cyclically Adjusted Book per Share is CHF79.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Biogen (XSWX:BIIB) has a current Cyclically Adjusted Book per Share of CHF79.98. The stock's GF Value™ is CHF153.91, compared to a current price of CHF173.46 — trading 12.7% above its estimated fair value. The current Cyclically Adjusted Book per Share is CHF79.98. Biogen's overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Biogen (XSWX:BIIB), the current Cyclically Adjusted Book per Share is CHF79.98 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (XSWX:BIIB) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of CHF173.46 is trading 12.7% above its estimated GF Value™ of CHF153.91.

Key valuation signals for XSWX:BIIB:

  • Cyclically Adjusted Book per Share: CHF79.98
  • GF Value™: CHF153.91 vs. price of CHF173.46 (12.7% above fair value)
  • GF Score™: 73/100 with 10 warning signs

No single metric tells the full story. See the XSWX:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
73GF Score

Get the complete analysis for XSWX:BIIB

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF173.46
Price
CHF153.91
GF Value